Skip to main content

DNage To Participate in EU Study on Biomarkers of Aging

NEW YORK (GenomeWeb News) – DNage, a wholly owned subsidiary of Dutch biotech Pharming Group, said today that it will participate in a five-year European study that aims to identify biomarkers of human aging.
 
The project, called MARK-AGE, is an EU-wide consortium of 26 industry and academic partners funded under the Seventh Research Framework Program. The EU has awarded a total of around €12 million ($19 million) for the study. 
 
Germany’s University of Konstanz is leading the project, which will study about 4,000 volunteers between 35 and 74 years old. Subjects will be recruited from the general population, as well as from families with long-living parents and siblings that have already been recruited as part of the EU’s ongoing “Genetics of Healthy Aging” project.
 
DNage said that it plans to use its proprietary animal models to discover novel biomarkers of aging, and that it will recruit patients that suffer from Cockayne syndrome and other premature-aging syndromes to validate the identified biomarkers.
 
The consortium expects that biomarkers identified through the project could be used to predict the onset of age-related diseases and may be used as diagnostic markers or as therapeutic targets.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.